Atrial Fibrillation Clinical Trials in Aurora, Colorado

5 studies are recruiting for atrial fibrillation in Aurora, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

   The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called el…

   Stage

   Phase 2

   Ages

   18 to 85

   Site

   UCHealth University of Colorado Hospital - Cardiology, Aurora, Colorado

   Locations

   29 in total

   Run by

   Bayer

   See if you can join NCT07625215 on ClinicalTrials.gov

2. A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System

   The purpose of this study is to evaluate the long-term safety and effectiveness of the FDA approved VARIPULSE catheter system for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF).

   Stage

   Not phased

   Ages

   22 and older

   Site

   Aurora Denver Cardiology Associates, Aurora, Colorado

   Locations

   22 in total

   Run by

   Biosense Webster, Inc.

   See if you can join NCT07227532 on ClinicalTrials.gov

3. The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

   REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in parti…

   Stage

   Phase 3

   Ages

   22 to 85

   Site

   University of Colorado, Aurora, Colorado

   Locations

   93 in total

   Run by

   Johns Hopkins University

   See if you can join NCT05836987 on ClinicalTrials.gov

4. Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

   The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated c…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Medical Center of Aurora, Aurora, Colorado

   Locations

   106 in total

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT04045665 on ClinicalTrials.gov

5. Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

   Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in b…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Colorado Hospital, Aurora, Colorado

   Locations

   187 in total

   Run by

   Yale University

   See if you can join NCT03907046 on ClinicalTrials.gov